Hepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease

Luca Valenti, Rosa M. Mendoza, Raffaela Rametta, Marco Maggioni, Chris Kitajewski, Carrie J. Shawber, and Utpal B. Pajvani

Hepatic Notch signaling is inappropriately activated in obese/insulin-resistant mouse models. Genetic or pharmacologic inhibition of hepatic Notch signaling in obese mice simultaneously improves glucose tolerance and reduces hepatic triglyceride content. As such, we predicted that Notch signaling in human liver would be positively associated with insulin resistance and hepatic steatosis. Here, we systematically survey Notch signaling in liver biopsy specimens, and show active Notch signaling in lean and obese adults, with expression of multiple Notch receptors and ligands. In morbidly obese patients undergoing bariatric surgery, we show that Notch activation positively correlates with glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase (PCK1) expression, key regulators of hepatic glucose output. We used immunofluorescence to identify active Notch signaling in hepatocytes and show highest activity in hyperglycemia, which we confirmed is a direct effect of hyperglycemia and insulin resistance. In a validation cohort of leaner individuals undergoing percutaneous liver biopsy for suspected nonalcoholic fatty liver disease (NAFLD), Notch activity showed independent positive association with insulin resistance and hepatic steatosis. Notably, Notch activity showed stronger correlation with the NAFLD activity score and alanine aminotransferase levels than with steatosis alone, suggesting that Notch activity is associated with nonalcholic steatohepatitis. In summary, this study establishes that Notch signaling is activated in human liver and may represent a therapeutic target for patients with obesity-related liver disease. 

Diabetes 62:4052–4062, 2013

Obesity manifests as multiple pathologic states in the liver. Insulin resistance in adipocytes results in unrestrained lipolysis, with consequent excess free fatty acid flux to the liver (1). In a parallel pathogenic process, excess adiposity leads to insulin resistance, which begets the fasting hyperglycemia of type 2 diabetes (T2D) (2). Compensatory hyperinsulinemia drives de novo lipogenesis (3), and coupled with an impaired ability to catabolize and export fatty acids (4), results in excess hepatocyte triglyceride accumulation, or nonalcoholic fatty liver disease (NAFLD), in the presence of a predisposing genetic background (5). Steatosis may be associated with hepatocellular damage and necroinflammatory changes, defining nonalcoholic steatohepatitis (NASH), which predisposes to cirrhosis and hepatocellular cancer (1). Interestingly, NASH further exacerbates hepatic insulin resistance through activation of forkhead box class O (FoxO) 1, the key transcriptional activator of glucose-6-phosphatase (G6PC) and phosphoenolpyruvate carboxykinase (PCK1), rate-limiting enzymes of gluconeogenesis and glycogenolysis, which combined regulate hepatic glucose output. This vicious cycle results in coincident NAFLD and T2D, which show independent associations with cardiovascular disease (6). No approved pharmacologic therapy is approved for NALFD, and although multiple T2D therapies are available, few show durability and long-term efficacy (7). As such, novel therapeutic directions are necessary to reduce overall obesity-related morbidity.

We previously showed that inhibition of hepatic Notch signaling protects from both obesity-induced glucose intolerance, by suppressing hepatic glucose output (8), and fatty liver, by reducing de novo lipogenesis (9). Notch signaling is highly conserved from lower organisms to primates and is critical for cell fate decision making, including regulation of cell specification and lineage restriction, depending on the cellular context (10). In mammals, cell surface Notch ligands of the Jagged (-1 and -2) and Delta-like (-1, -3, -4) families bind one of four Notch receptors (Notch1–4) on a neighboring cell, resulting in a series of cleavage events that culminate in the transcription of canonical Notch targets, the hairy enhancer of split (HES) and Hes-related (HEY) family of genes (11). Homozygous null alleles in this pathway result in embryonic lethality in mice (12–14) and loss-of-function mutations in severe developmental defects in affected individuals (15,16), proving the critical role of Notch signaling to regulate cell fate decisions in normal development.

Less is known about Notch signaling in mature tissue. Increased Notch expression and function has been shown in cancer and tumor angiogenesis (17–19), but there are few reports of expression analysis of Notch pathway proteins in developed, non-neoplastic tissue. In the liver, Notch proteins are constitutively expressed in multiple cell types (20,21), with increased expression in hepatocytes after partial hepatectomy (22). In rat models, normal liver regeneration was prevented by genetic inhibition of hepatocyte Notch signaling (23). As such, we predicted that the Notch-signaling apparatus is present in mature liver and may be induced by obesity-induced hepatocyte damage. Our initial characterization of Notch signaling in murine liver demonstrated that Notch target gene expression is, in fact, increased in mouse models of obesity and insulin resistance (8). Interestingly, genetic (8) or pharmacologic (11,24,25) blockade of hepatocyte Notch signaling resulted in parallel inhibition of hepatic glucose production (8) as well as triglyceride accumulation (9), lowering the overall atherosclerotic burden in obese mice (26).
Conversely, constitutive activation of hepatocyte Notch signaling caused glucose intolerance and fatty liver (8, 9). These studies suggested that the Notch pathway is active through adulthood in rodent liver, is inappropriately stimulated by obesity, and may be manipulated to reduce the obesity-related metabolic disease burden.

On the basis of these rodent studies, we hypothesized that Notch signaling is similarly functional and may correlate with disease severity in patients with hepatic insulin resistance and NAFLD. In this study, we show that Notch proteins and ligands are expressed in lean and obese subjects and that increased activation of this pathway, as assessed by expression of Notch target genes of the HES/HEY family, positively correlates with gluconeogenic gene expression and hyperglycemia in a cohort of morbidly obese patients undergoing bariatric surgery. In a validation cohort across a range of BMIs, we confirmed the positive association between HES/HEY family genes and insulin resistance as well as demonstrated an independent positive association with hepatic fat content. Finally, we show that hepatic Notch signal activation correlates better with measures of liver inflammation than with simple steatosis (SS), suggesting that it may represent a marker of the transition from SS to NASH. This work establishes that Notch signaling correlates and potentially represents a novel therapeutic target for both arms of obesity-related liver disease, T2D and NAFLD.

RESEARCH DESIGN AND METHODS

Subjects. The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board and ethical committee of the Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca’ Granda. Each subject gave written informed consent. Demographic and anthropometric features, arterial blood pressure, medical history, and medications were recorded for all patients and are summarized in Table 1. A needle liver biopsy was performed in all patients. The specimen was formalin-preserved for histological and immunofluorescence analysis. Part of the sample was included in RNA later (Ambion, Carlsbad, CA), immediately frozen in liquid nitrogen, and stored at −80°C for RNA analysis.

| TABLE 1 | Demographic and clinical features of subjects included in the study subdivided according to the case series (bariatric surgery and hepatology clinic) and liver histology |
|---------|---------------------------------------------------------------------------------|
| **Bariatric surgery** | **Hepatology clinic** |
| Normal | SS | NASH | P value | Normal | SS | NASH | P value |
| n (%) | | | | | | | |
| Sex (n) | | | | | | | |
| Female | 5 (12) | 14 (33) | 23 (55) | 0.035 | 7 (18) | 11 (29) | 20 (53) | 0.23 |
| Male | 0 | 1 | 9 | | 7 | 10 | 20 | |
| Age (years) | 44 ± 4 | 40 ± 9 | 42 ± 10 | 0.73 | 45 ± 12 | 54 ± 9 | 51 ± 12 | 0.33 |
| BMI (kg/m²) | 40.8 ± 10 | 40.5 ± 10 | 43.5 ± 8 | 0.54 | 25.1 ± 2.4 | 27.5 ± 3.4 | 28.7 ± 4.2 | 0.11 |
| Abdominal circumference (cm) | | | | | 94 ± 6 | 102 ± 6 | 112 ± 21 | 0.05 |
| Glucose (mg/dL) | 83 ± 8 | 88 ± 5 | 117 ± 56 | 0.09 | 92 ± 7 | 116 ± 35 | 111 ± 30 | 0.24 |
| Insulin (U/mL) | | | | | 8.4 ± 2.2 | 14.1 ± 1.9 | 16.0 ± 1.5 | 0.034 |
| HOMA-IR | | | | | 1.7 ± 0.4 | 3.6 ± 1.7 | 3.8 ± 1.7 | 0.018 |
| Glucose tolerance | | | | | | | 0.001 |
| IS [n (%)] | | | | | 7 (100) | 2 (18) | 4 (20) | |
| IR [n (%)] | | | | | 0 | 5 (46) | 10 (50) | |
| T2D [n (%)] | | | | | 0 | 4 (36) | 6 (30) | |
| Cholesterol (mg/dL) | 215 ± 31 | 211 ± 36 | 214 ± 41 | 0.96 | 191 ± 47 | 201 ± 37 | 188 ± 40 | 0.66 |
| Triglyceride (mg/dL) | 99 ± 54 | 155 ± 95 | 157 ± 54 | 0.30 | 94 ± 27 | 98 ± 48 | 115 ± 54 | 0.51 |
| HDL (mg/dL) | 73 ± 11 | 52 ± 9 | 46 ± 12 | <0.0001 | 55 ± 15 | 57 ± 28 | 44 ± 14 | 0.17 |
| Steatosis (%) | 2 ± 1 | 17 ± 13 | 61 ± 21 | <0.0001 | 3 ± 2 | 19 ± 14 | 52 ± 23 | <0.0001 |
| ALT (U/mL) | 18 ± 5 | 26 ± 9 | 39 ± 25 | 0.03 | 22 ± 8 | 40 ± 32 | 66 ± 46 | 0.02 |

Data represent average ± SD unless indicated otherwise. IR, insulin-resistant; IS, insulin-sensitive.
Laboratories). Images were captured with a Nikon ECLIPSE E800 microscope and a Nikon DXM 1200 digital camera and processed with Image ProPlus software. Staining was quantitated in a blinded fashion from 1 (low expression) to 4 (high expression), independently by three investigators, and scores were averaged.

**Quantitative RT-PCR.** We isolated RNA with Trizol (Invitrogen), synthesized cDNA with Superscript III RT (Invitrogen), and performed quantitative PCR with a DNA Engine Opticon 2 System (Bio-Rad) and GoTaq SYBR Green (Promega). Absolute mRNA levels were determined for each gene using species- and primer-specific standard curves, then normalized to 18S, and are presented as relative transcript levels (fg/ng 18S). Primer sequences are available upon request.

**Luciferase assays.** Hepa1c1c7 cells were transfected with the Rbp-Jk reporter luciferase construct, as previously described (8), and then incubated in serum-free medium with variable glucose content in the presence or absence of 10 nmol/L insulin or 10 nmol/L glucagon.

**Hepatocyte studies.** We isolated and cultured primary mouse hepatocytes as described (8) and obtained human primary hepatocytes from Invitrogen. For gene and protein expression studies, we treated hepatocytes with variable concentrations of glucose, and/or 10 nmol/L insulin (Sigma-Aldrich) for 3 h, with all experiments completed by 24 h after isolation.

**Statistical analysis.** Results are shown as mean ± SEM. ANOVA was used for comparison of means among groups. Gene expression levels were correlated by the Pearson correlation. The association between *HES1* expression (above the median) and insulin resistance of T2D was evaluated by multivariate logistic regression analysis adjusted for age, steatosis, and BMI. Independent predictors of *HES1* expression were evaluated at multivariate regression analysis (generalized linear model), including NAS and insulin levels, the variables most significantly associated at univariate analysis. Differences were considered significant at *P* < 0.05 (two-tailed).

**RESULTS**

**Human liver has a functional, evolutionarily conserved Notch-signaling apparatus.** To clarify the role of Notch signaling in the postdevelopment human liver, we characterized liver Notch and ligand expression in insulin-sensitive subjects with a histologically normal liver. We found that in these subjects, all four Notch receptors were expressed, with relative higher levels of *NOTCH1* and *NOTCH2* (Fig. 1A, left panel). In addition, all five Notch ligands were detectable by quantitative PCR, with *JAG1* and *JAG2* showing greater expression than Delta-like ligands. Of note, this expression pattern is broadly similar to the distribution observed in murine liver (Fig. 1A, right panel) as well as in mouse hepatocytes (8). Generally, expression of *NOTCH1* and other Notch genes covaried (Fig. 1B) as well as with *HES/HEY* family target genes (Fig. 1C), but showed no correlation with housekeeping genes (*ACTB*, *GAPDH*) and a nonsignificant trend toward a negative correlation with Notch ligand expression (data not shown). These data show that Notch signaling components are present in mature liver and that relative expression is evolutionarily conserved.

**Hepatic Notch signaling correlates with G6PC/PCK1 expression and is increased in patients with T2D.** Because Notch proteins and ligands are expressed in human liver, we hypothesized that Notch signaling may be
increased in obesity and insulin resistance as in mouse models. We performed a pilot study in 42 morbidly obese patients undergoing liver biopsy at time of gastric banding. Full demographic and clinical information is summarized in Table 1, but most of the subjects were female (76%), with SS or NASH (88%), and nondiabetic (79%). Expression of canonical Notch target genes of the HES/HEY family positively correlated with hepatic expression of G6PC and PCK1 (Table 2 and Fig. 2A). Of note, we saw no correlation in severely obese patients between Notch signaling and age, sex, or BMI (data not shown), which suggests that the correlations between HES/HEY and G6PC/PCK1 were independent of overall adiposity, but correlations persisted or even strengthened when

FIG. 1. Continued.
diabetic patients were excluded from the analysis (Table 2).

Liver consists primarily of hepatocytes, but also non-hepatocyte residents, including endothelial, phagocytic Kupffer, and stellate cells (31). The relative contribution of hepatocytes to overall hepatic Notch signaling was unclear from gene expression studies from the whole liver, so we performed immunochemistry for Notch targets on a representative subset of patients across a range of glycemic control. We observed predominantly hepatocyte staining of Notch targets HEY1 and HEYL (Fig. 2B). HEY1 hepatocyte staining and HEYL expression was very well correlated (Fig. 2C), as was HEYL staining and HEYL expression (not shown), suggesting hepatic gene expression is a good surrogate for hepatocyte protein levels. Further, HEY1 gene expression strongly correlated with HES1, HEY1, and other Notch targets (Fig. 2D and data not shown), allowing HEY1 staining as a surrogate for global hepatocyte Notch activation. Having validated the technique, we next examined sections from age- and BMI-matched normoglycemic and diabetic patients and noted a marked increase in HEY1 and HEYL staining in hyperglycemic patients (Fig. 2E and F and data not shown). These data establish that Notch signaling is present in adult hepatocytes and increased in T2D.

FIG. 2. Notch activity in liver increases with hyperglycemia. A: Correlation of Notch targets of the HES/HEY family with the expression of genes controlling hepatic glucose production, G6PC and PCK1. B: Representative liver sections, stained with antibodies to HEY1 (green, left) or HEYL (red, middle) and counterstained with DAPI (blue), with merged image (right). Hepatic HEY1 expression correlates with Hey1 staining (P < 0.001 by ANOVA) (C) and HES1 expression (P < 0.001 by ANOVA) (D). Immunofluorescence (E) and quantitation (F) of staining for HEY1 in formalin-fixed liver sections from non-T2D and T2D patients undergoing liver biopsy during gastric bypass surgery. The very bright spots are autofluorescent erythrocytes and are not included in the quantitation. Data show means ± SEM. *P < 0.05 vs. non-T2D patients. AU, arbitrary units.

### TABLE 2

Correlation of Notch gene targets with G6PC and PCK1 expression in 42 patients undergoing bariatric surgery

| Gene | G6PC | PCK1 |
|------|------|------|
|      | r    |      | p    |      |
|      | Pearson |      | Pearson |      |
| HES1 | 0.39  | 0.011 | 0.47 | 0.0016 |
| HES6 | 0.24  | NS    | 0.33 | 0.018  |
| HES7 | 0.27  | NS    | 0.35 | 0.033  |
| HEY1 | 0.27  | NS    | 0.42 | 0.002  |

expression (not shown), suggesting hepatic gene expression is a good surrogate for hepatocyte protein levels. Further, HEY1 gene expression strongly correlated with HES1, HEY1, and other Notch targets (Fig. 2D and data not shown), allowing HEY1 staining as a surrogate for global hepatocyte Notch activation. Having validated the technique, we next examined sections from age- and BMI-matched normoglycemic and diabetic patients and noted a marked increase in HEY1 and HEYL staining in hyperglycemic patients (Fig. 2E and F and data not shown). These data establish that Notch signaling is present in adult hepatocytes and increased in T2D.
Hepatic Notch signaling is increased in insulin resistance. The positive correlation of HES/HEY family genes with G6PC/PCK1 in obese patients (Table 2), coupled with increased HEY1 staining in hyperglycemia, suggested that Notch signaling is increased in insulin-resistant liver. To determine whether hepatic Notch signaling was similarly induced in leaner patients and might precede development of frank diabetes in insulin-resistant liver, the researchers measured HEY1 expression in nondiabetic and type 2 diabetic patients.

**TABLE 3**

*HES1* expression correlates independently with HOMA-IR as well as NAS scores

|                      | Correlation coefficient | SE    | Unadjusted P value* | Adjusted P value** |
|----------------------|-------------------------|-------|---------------------|--------------------|
| Age (per 10 years)   | 0.03                    | 0.05  | NS                  | NA                 |
| BMI (kg/m²)          | 0.01                    | 0.02  | NS                  | NA                 |
| Glucose (per 10 mg/dL increase) | 0.00           | 0.02  | NS                  | NA                 |
| Insulin              | 0.02                    | 0.01  | 0.002               | 0.03               |
| ALT (per 10 IU/L increase) | 0.07                  | 0.02  | 0.003               | NA                 |
| HOMA-IR              | 0.11                    | 0.03  | 0.002               | NA                 |
| % Steatosis (per 10% increase) | 0.05          | 0.02  | 0.011               | NA                 |
| NAS                  | 0.11                    | 0.03  | <0.0001             | 0.03               |

NA, not addressed. *At univariate analysis (generalized linear model). **At multivariate analysis (generalized linear model) including insulin levels and NAS score, the strongest variables related to insulin resistance and histological damage, respectively, at univariate analysis.
resistance, we analyzed specimens from 38 consecutive outpatients undergoing percutaneous liver biopsy. Full demographics can be found in Table 1, but this group was 97% male, with an average BMI in the overweight range (25–30 kg/m²). In these patients, we again noted that HES/HEY family genes correlated with G6PC and PCK1, as well as with each other (data not shown), suggesting that Notch and gluconeogenic gene expression coregulation is not specific to obese patients. As in the bariatric surgery cohort, Notch signaling did not vary by age, BMI, or abdominal circumference, but as predicted, we found a significant positive correlation with Notch targets (HES1) and plasma FIG. 3. Notch activity in hepatocytes increases with hyperglycemia. Notch-luciferase reporter (Csl-luc) expression in Hepa1c1c7 hepatoma cells (A), and Notch target gene expression in primary hepatocytes from mice (B) or human donors (C) is increased with transient exposure to hyperglycemic (25 mmol/L glucose) conditions. Insulin reduces Notch activity in Hepa1c1c7 hepatoma cells when cultured in normoglycemic (D), but not hyperglycemic conditions (E), even as glucagon has a synergistic effect. F: Insulin fails to repress Hes1 expression in hepatocytes derived from mice lacking hepatic Notch signaling. G: Hyperglycemic-induced Notch reporter expression in Hepa1c1c7 hepatoma cells is abrogated by transduction with N1-decoy, which blocks ligand-dependent Notch signaling. Data show means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. 5 mmol/L glucose or control (Cre- or GFP-transduced) cells. AU, arbitrary units.
insulin levels (not shown) and HOMA-IR, independent of confounding factors (Table 3), which was not mitigated by exclusion of diabetic patients (data not shown). Multivariate logistic regression analysis showed increased HES1 expression was positively associated with the presence of insulin resistance of diabetes (odds ratio [OR] 2.11 [95% CI 1.5–3.8]), together with age (OR 1.17 [95% CI 1.05–1.40]) and steatosis (OR 5.5 [95% CI 1.3–53]), independently of BMI. These data establish that Notch activation is found in the insulin-resistant liver, preceding frank hyperglycemia and the development of diabetes.

Insulin and hyperglycemia directly and reciprocally affect Notch signaling. To test the hypothesis that the apparent regulation of hepatic Notch signaling by insulin resistance and hyperglycemia is direct and cell-autonomous, we transfected hepatoma cells with a Notch-reporter luciferase construct and found increased Notch activation in hyperglycemic as opposed to basal conditions (Fig. 3A). Similarly, endogenous Notch target expression was higher in primary mouse or human hepatocytes transiently exposed to hyperglycemia (Fig. 3B and C). Insulin treatment had the opposite effect on Notch signaling, with insulin-treated cells showing decreased reporter activation (Fig. 3D). Interestingly, the inhibitory effect of insulin, but not a synergistic effect of glucagon, was lost in cells chronically cultured in hyperglycemic conditions (Fig. 3E). Further, insulin was no longer able to repress Hes1 expression in primary hepatocytes derived from mice lacking Rbp-Jk (8), the common transcriptional effector of Notch1–4 signaling (Fig. 3F). Similarly, pharmacologic application of a novel Notch antagonist, an ectodomain “decoy” that quenches ligand-dependent Notch signaling (24), abrogated hyperglycemia-induced Notch-reporter activity (Fig. 3G). In sum, these data suggest a cell-autonomous, dynamic regulation of hepatic Notch signaling by metabolic stimuli.

Hepatic Notch signaling is positively correlated with hepatic steatosis and inflammation. Beyond the positive correlation between HES/HEY gene expression and measures of insulin resistance and hyperglycemia, we predicted that Notch signaling would correlate with hepatic lipid content and markers of necroinflammation. Indeed, when patients are subdivided by liver histology, we find that HES1 and other Notch target genes are strongly upregulated across the spectrum from normal liver to SS to NASH, and further still in insulin resistance (Fig. 4A or in patients with T2D (Fig. 4B). Notch target staining was similarly increased in hepatocytes of NASH patients compared with SS patients (Fig. 4C).

In fact, HES1 expression more closely correlated to measures of hepatic inflammation than to steatosis, with stronger coefficients of correlation with NAS and ALT levels than with the percentage of steatosis (Fig. 5A–C and Table 3). As such, patients with a NAS score of 0–2, correlating with a low risk of NASH (29,32), had lower Notch, ligand, and HES/HEY family gene expression than those with scores of 3 or higher (Fig. 5D–F). Furthermore, the NAS score was associated with HES1 expression independently of insulin resistance (Table 5). In sum, these data suggest that hepatic Notch signaling is elevated in insulin resistance as well as in NASH.
DISCUSSION
Notch signaling has been extensively studied in the context of differentiation or cancer (10), but its metabolic functions are novel. Rodent studies have demonstrated a postdevelopment role for Notch in the regulation of obesity-induced insulin resistance/diabetes (8,26) and in liver fat accumulation (9), but whether this would translate to human disease was unclear. This work answers two important questions: hepatic Notch signaling is 1) present in human liver/hepatocytes, and 2) its activation is tied

FIG. 5. Notch activity correlates with hepatocyte necroinflammation. Liver HES1 expression was plotted against NAS (A), serum ALT level (B), and percentage of hepatic steatosis in patients undergoing percutaneous liver biopsy (C). Notch target (D), protein (E), and ligand gene expression (F) are increased in liver from patients with higher NAS (NAS 3+) compared with patients at low risk for steatohepatitis (NAS 0–2). Data show means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 vs. NAS 0–2. AU, arbitrary units.
to the metabolic state of the organism, with an independent positive correlation with measures of insulin resistance and hepatic steatosis/inflammation. Notch signaling appears to be inappropriately reactivated in the insulin-resistant liver, repring its developmental role and reassociating with its molecular partners from differentiation that drives the metabolic effects of Notch signaling. For instance, the Notch transcriptional effector Rbp-Jk binds to and activates FoxO1 (33), a key transcriptional activator of hormone-stimulated hepatic glucose production (2,34), increasing functional hepatic insulin resistance (8). Similarly, Notch signaling activates the nutrient-sensitive mTorc1 pathway in the liver, increasing de novo lipogenesis and hepatic triglyceride (9). Mouse models with reduced hepatic glucose production often have compensatory fatty liver due to reoriented carbon flux; for instance, FoxO1-knockout mice (35,36) or mice treated with glucokinase activators (37). Reduced Notch action allows the dissociation of insulin-signaling pathways in the liver, redressing insulin resistance without causing undue nutrient sensitivity, allowing for this rare dual therapeutic benefit independent of effects on body weight or adiposity.

It is intriguing that Notch activation more strongly correlates with markers of steatohepatitis, including the NAS and ALT levels, than with steatosis itself. With better imaging techniques (38), clinicians can increasingly diagnose excess hepatic fat (5). NAFLD is extraordinarily common, with a prevalence approaching 30% in many populations (39), leaving a therapeutic dilemma because only a subset of patients progress to NASH (40). As such, increased Notch signaling may represent a biomarker or even a causative factor for progression from SS to NASH. It is noteworthy that Notch pathway activation has similarly been found in human hepatocellular carcinoma (41) and causes hepatic fibrosis and tumor formation in mice (41–43), which potentially explains the predisposition of patients with NASH to develop cirrhosis and hepatocellular carcinoma (44,45).

One of the major limitations of this type of observational study is that we are able to detect Notch signaling, as well as markers of insulin sensitivity and hepatic fat, at one moment in time. Longitudinal studies (46) are required to determine whether altered Notch signaling predated or predicts the development of worsening steatosis or progression to NASH and hepatocellular carcinoma. Similarly, whether increased Notch signaling precedes development of insulin resistance or heralds the transition to frank diabetes is unknown. In addition, it would be of interest to know whether interventions to reduce insulin resistance, or steatosis and associated inflammation (47,48), also reduce hepatic Notch signaling. Finally, whether higher Notch signaling seen in NASH patients reflects both hepatocyte and nonhepatocyte contribution requires clarification, because this may shed light on how Notch signals are transduced. These future studies will inform the question whether Notch may be a therapeutic target for insulin-resistance/diabetes or NASH.

It is premature, given these lingering questions and potential safety concerns, to propose a clinical trial with the use of Notch inhibitors, which are already in advanced clinical development for cancer (49,50), for treatment of T2D or NASH. This temptation exists, however, in the current era of pandemic obesity. Our data suggest the possibility of alternative uses for these existing therapeutics to combat the various faces of obesity-related metabolic disease in the 21st century.

ACKNOWLEDGMENTS

The work was partly funded by National Institutes of Health grants DK-093604 (U.B.P.) and 5R01-CA136673 (C.J.S.), a Columbia Diabetes and Endocrinology Research Center Pilot and Feasibility Grant (U.B.P.), the Edward Mallinckrodt, Jr., Foundation Grant (U.B.P.), and Ricerca Corrente Fondazione IRCCS Ca’ Granda, Milano (L.V.).

No potential conflicts of interest relevant to this article were reported.

L.V. and C.J.S. analyzed data and wrote the manuscript. R.M.M. and C.K. designed and performed experiments and analyzed data. R.R. collected and managed biological samples for RNA analysis. M.M. selected and collected histological samples and reviewed histological samples. U.B.P. designed and performed experiments, analyzed data, and wrote the manuscript. U.B.P. is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank Domenico Accili and members of the Accili Laboratory at Columbia University, as well as members of the Metabolic Liver Diseases Laboratory at the University of Milan, for insightful discussion of the data, and Robin Goland at Columbia University for assistance in study design and implementation. The authors acknowledge excellent technical support from Jessie Lee and Taylor Lu at Columbia University, and Rosa Lombardi, Anna Ludovica Pracanzani, Enrico Mozzi, and Silvia Fargion at the University of Milan for collection of clinical data and biological samples.

REFERENCES

1. Savage DB, Temple RK. Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 2010;21:329–336
2. Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab 2011;14:149–19
3. Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 2010;107:3441–3446
4. Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634–642
5. Dongiovanni P, Anstee QM, Valenti L. Genetic Predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment. Curr Pharm Des 2013;19:5219–5238
6. Villanova N, Moscatiello S, Ramilli S, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473–480
7. Kahn SE, Haffner SM, Heise MA, et al.; ADOPt Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427–2443
8. Pajvani UB, Shawber CJ, Samuel VT, et al. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat Med 2011;17:961–967
9. Pajvani UB, Qiang L, Kangsamaksin T, Kitajewski J, Ginsberg HN, Accili D. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 2013;19:1054–1060
10. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339–363
11. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27:512–5137
12. Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T. Notch signaling in the vasculature: insights from zebrafish, mouse and man. Bioessays 2004;26:229–234
16. Flynn DM, Nijjar S, Hubscher SG, et al. The role of Notch receptor expression in bile duct development and disease. J Pathol 2004;204:55–64
17. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991;66:649–661
18. Haruki N, Kawaguchi KS, Eichenberger S, et al. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. Cancer Res 2005;65:3555–3561
19. Gallahan D, Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene 1997;14:1883–1890
20. Nijjar SS, Crosby HA, Wallace L, Hubscher SG, Strain AJ. Notch receptor expression in adult human liver: a possible role in bile duct formation and hepatic neovascularization. Hepatology 2001;34:1184–1192
21. Nijjar SS, Wallace L, Crosby HA, Hubscher SG, Strain AJ. Altered Notch ligand expression in human liver disease: further evidence for a role of the Notch signaling pathway in hepatic neovascularization and biliary ductular defects. Am J Pathol 2002;160:1695–1703
22. Köhler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK. Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology 2004;39:1056–1065
23. Wang L, Wang CM, Hou LH, et al. Disruption of the transcription factor recombination signal-binding protein-Jc (RBP-J) leads to veno-occlusive disease and interfered liver regeneration in mice. Hepatology 2009;49:269–277
24. Funahashi Y, Hernandez SH, Das I, et al. A Notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res 2008;68:4727–4735
25. Funahashi Y, Shawber CJ, Sharma A, Kanamaru E, Choi YK, Kitajewski J. Notch modulates VEGF action in endothelial cells by inducing the matrix metalloproteinase activity. Vasc Cell 2011;3:2
26. Fukuda D, Aikawa E, Swirski FK, et al. Notch ligand delta-like-4 blockade attenuates atherosclerosis and metabolic disorders. Proc Natl Acad Sci U S A 2012;109:E1868–E1877.
27. Rametta R, Mozzi E, Dongiovanni P, et al. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Int J Obes 2013;37:986–992.
28. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008;294:E15–E26
29. Kleiner DE, Brunt EM, Van Natta M, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.
30. Shawber CJ, Funahashi Y, Francisco E, et al. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J Clin Invest 2007;117:3369–3382
31. Baratta JL, Ngo A, Lopez B, Kasahwalla N, Longmuir KJ, Robertson RT. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. Histochem Cell Biol 2006;131:713–726
32. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344–353
33. Kitamura T, Kitamura YI, Funahashi Y, et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. J Clin Invest 2007;117:2477–2485
34. Matsumoto M, Pocai A, Rossetti L, Depinho RA, Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab 2007;6:208–216
35. Tao R, Wei D, Gao H, Liu Y, Depinho RA, Dong XC. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem 2011;286:14681–14690
36. Haesler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D. Impaired generation of 12-hydroxybile acids links hepatic insulin signaling with dyslipidemia. Cell Metab 2012;15:65–74
37. De Comninck F, Kargar C, Ilc C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013;168:339–353
38. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009;51:433–445
39. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013;19:5169–5176.
40. Loria P, Adinolfi LE, Bellentani S, et al.; NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (ABSF) Expert Committee. Dig Liver Dis 2010;42:272–282.
41. Villanueva A, Alsinet C, Yang K, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012;143:1660–1669.e1667
42. Tschaharganeh DF, Chen X, Latzko P, et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 2013;144:1530–1542.e12
43. Chen Y, Zheng S, Qi D, et al. Inhibition of Notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS ONE 2012;7:e46512
44. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330–344.
45. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012;10:1342–1359.e1342.
46. Musso G, Cassader M, Bo S, De Micheli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013;62:1189–1190
47. Lavine JE, Schwimmer JB, Van Natta ML, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659–1668.
48. Sanyal AJ, Chalasani N, Kowdle RV, et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675–1685
49. Noguera-Troiese I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444:1032–1037
50. Wu Y, Cai-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature 2010;464:1052–1057